Life insurance after prostate cancer

Generally a better outcome than expected

Prostate cancer is among the more favourably assessed cancers in life insurance underwriting. Many cases are found early through PSA testing, many are low grade, and outcomes for localised low-grade disease are good.

For an applicant whose disease was confined to the prostate, low grade, treated successfully, with PSA stable since and a reasonable period elapsed, standard rates are a realistic outcome. Ratings are common at higher grades or stages. Declines are the minority and are associated with advanced disease or rising PSA after treatment.

The Gleason score

This is the number an underwriter looks for first, and it does more work than anything else on the page.

The Gleason score describes how abnormal the cancer cells appeared under a microscope, based on the two most prominent patterns in the sample. It is reported as two numbers added together, and the components matter as well as the total, because the same total can be reached in ways that behave differently. Some pathology reports also express this as a Grade Group.

Lower scores indicate disease behaving less aggressively and are assessed considerably more favourably. Higher scores shift the assessment substantially, and they carry more weight than the PSA number at diagnosis does.

If you know only one thing from your pathology report before applying, this is the one to know.

PSA before and after

PSA is a blood test used both in detection and in follow-up, and the two uses are weighted differently.

PSA at diagnosis provides context alongside the Gleason score and the stage.

PSA since treatment is where underwriters focus. After surgery to remove the prostate, PSA would be expected to fall to a very low level and stay there. After radiation, the pattern differs but a stable low reading is still the expectation.

A rising PSA after treatment, sometimes described as biochemical recurrence, is one of the more significant findings in a prostate file. It suggests disease activity, and it changes the assessment materially even where the man feels entirely well and no other sign has appeared.

The trend across several readings tells an underwriter far more than any single value. Where your urologist has been monitoring this, that record is the most useful document in the file.

Active surveillance

A large number of Canadian men with low-grade, localised prostate cancer are managed by monitoring rather than immediate treatment, with regular PSA testing and periodic biopsies.

Insurers understand this. Active surveillance is a recognized clinical approach and is not read as untreated or neglected disease.

It is assessed on its own terms. What matters is the Gleason score, the stability of PSA over time, and the findings of any repeat biopsies. A man on stable active surveillance with low-grade disease and steady readings over several years is often insurable on reasonable terms.

Because there is no treatment end date, the usual “how long since treatment finished” question does not apply in the same way, and the duration of stable surveillance takes its place.

Treatment, and what follows it

Radical prostatectomy. Surgical removal. Underwriters look at the surgical pathology, including whether margins were clear and whether the disease had extended beyond the prostate, and at PSA since.

Radiation. Assessed on the same underlying disease characteristics, with attention to the PSA pattern afterwards, which behaves differently than after surgery.

Hormone therapy. Sometimes given alongside radiation or for more advanced disease. Ongoing hormone therapy is generally treated as continuing treatment, which can delay eligibility in the same way endocrine therapy does in other cancers.

Age makes this different from most cancer files

Prostate cancer is diagnosed most often in later life, and that shapes the assessment in a way worth naming.

An application after prostate cancer frequently comes from someone in their sixties or seventies, where the underwriting question is not only about the cancer but about everything else on the file at that age: blood pressure, cardiovascular history, weight and so on. The cancer is assessed within that whole picture.

It also means the practical options may be shaped as much by age as by the diagnosis. What tends to be available at different ages is covered in coverage for seniors and over 70.

Applying

Bring the specifics: Gleason score or Grade Group, PSA at diagnosis, the treatment given with dates, PSA readings since, and whether you are on active surveillance or hormone therapy. Have your urologist’s name.

Ask what waiting period applies to your grade and stage, rather than applying and being postponed.

Apply fully underwritten first. Prostate cancer is an area where insurers differ, particularly on active surveillance cases and on intermediate Gleason scores.

The boundary

This page describes underwriting, not medicine. Nothing here is information about prostate cancer, its treatment or its monitoring, and those decisions rest entirely with your urologist and your medical team.